26nnev86jtk
nowatorka
Dołączył: 02 Sty 2011
Posty: 50
Przeczytał: 0 tematów
Ostrzeżeń: 0/3
Skąd: England
|
 Wysłany: Czw 5:09, 27 Sty 2011 Temat postu: WuXi links with Janssen division on preclinical se |
|
|
WuXi PharmaTech, the R&D outsourcing company based in Shanghai, China, has announced an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) to collaborate on preclinical services and associated training.
WuXi will provide toxicology and other non-clinical services to J&JPRD, a division of Janssen Pharmaceutica N.V. Its partner will supply training and other services – to be reimbursed by WuXi – to establish a Good Laboratory Practice (GLP) quality system and the technical capabilities to meet international standards at WuXi’s toxicology facility in Suzhou,[link widoczny dla zalogowanych], China.
Construction of this facility, the largest of its kind in China with 314,000 sq ft of space, was completed at the end of 2008. Last year, WuXi hired a management team “with extensive international experience” and made substantial progress in training an initial team of technicians in GLP services, the company noted.
The Suzhou facility is currently supplying non-GLP toxicology services as well as client-sponsored GLP validation studies. It remains on target to start offering GLP toxicology studies by mid-2010, WuXi said.
The new partnership with J&JPRD builds on an existing agreement under which WuXi provides Janssen with integrated pharmaceutical R&D services. In October 2008,[link widoczny dla zalogowanych], the Chinese company went from being a preferred research services provider to J&JPRD for discovery chemistry to supplying integrated research services in the areas of discovery chemistry, discovery biology,[link widoczny dla zalogowanych], chemical and analytical development services, formulation, and preclinical and bioanalytical services.
“We believe that China, with its high-quality scientific talent and favourable cost structure, is destined to become a major centre for toxicology services over the next decade,” commented Dr Ge Li, chairman and chief executive officer of WuXi PharmaTech.
“We aim to become a leading provider of these services and to add toxicology to WuXi’s broad,[link widoczny dla zalogowanych], integrated platform of laboratory and preclinical services,” he added.
For the original news article,[link widoczny dla zalogowanych], please go to
Post został pochwalony 0 razy
|
|
FAQ 
